Literature DB >> 2492170

Effects of oral morphine on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease.

R W Light1, J R Muro, R I Sato, D W Stansbury, C E Fischer, S E Brown.   

Abstract

Previous studies have shown that opiates increase the maximal external work performed at exhaustion in patients with chronic obstructive pulmonary disease (COPD). The mechanism responsible for this improvement in exercise tolerance is unknown. The purpose of this study was to determine the effects of an oral morphine solution (0.8 mg/kg) on the exercise tolerance, perception of dyspnea, and arterial blood gases of patients with COPD. Thirteen eucapnic patients with stable COPD (FEV1 = 0.99 +/- 0.48) underwent duplicate incremental cycle ergometer tests to exhaustion (Emax) after the ingestion of placebo and after the ingestion of morphine. After the ingestion of morphine, the maximal workload increased by 18% (p less than 0.001) and the VO2 increased by 19.3% (p less than 0.001). Ten of the 13 patients had a higher ventilation at Emax after morphine ingestion. Despite the higher ventilation at Emax after morphine, the mean Borg score was not significantly higher. At Emax after morphine ingestion, the PaO2 (65.8 +/- 11.6 mm Hg) was significantly lower and the PaCO2 (43.5 +/- 8.3 mm Hg) was significantly higher than at Emax after placebo (71.9 +/- 15.5 and 38.3 +/- 8.5, respectively). When data at the highest equivalent workload were analyzed, the ventilation and the Borg scores were significantly lower, whereas the VO2 and VCO2 were comparable. From this study, we conclude that the administration of opiates can substantially increase the exercise capacity of patients with COPD. The improved exercise tolerance appears to be related to both a higher PaCO2 resulting in lowered ventilation requirements for a given workload and also to a reduced perception of breathlessness for a given level of ventilation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2492170     DOI: 10.1164/ajrccm/139.1.126

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  20 in total

1.  Killing the symptom without killing the patient.

Authors:  Romayne Gallagher
Journal:  Can Fam Physician       Date:  2010-06       Impact factor: 3.275

2.  Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease.

Authors:  R Leung; P Hill; J Burdon
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

Review 3.  The management of dyspnea in cancer patients: a systematic review.

Authors:  Raymond Viola; Cathy Kiteley; Nancy S Lloyd; Jean A Mackay; Julie Wilson; Rebecca K S Wong
Journal:  Support Care Cancer       Date:  2008-01-24       Impact factor: 3.603

Review 4.  Palliative medicine.

Authors:  R J George; A L Jennings
Journal:  Postgrad Med J       Date:  1993-06       Impact factor: 2.401

Review 5.  The outpatient diagnosis and management of chronic obstructive pulmonary disease: pharmacotherapy, administration of supplemental oxygen, and smoking cessation techniques.

Authors:  R M Schapira; L F Reinke
Journal:  J Gen Intern Med       Date:  1995-01       Impact factor: 5.128

6.  Suffering and dying in cancer patients. Research frontiers in controlling confusion, cachexia, and dyspnea.

Authors:  N MacDonald
Journal:  West J Med       Date:  1995-09

7.  Clinical application of nebulized opioids for treatment of dyspnoea in patients with malignant disease.

Authors:  M Farncombe; S Chater
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

Review 8.  The symptomatic relief of dyspnea.

Authors:  Giovanni Elia; Jay Thomas
Journal:  Curr Oncol Rep       Date:  2008-07       Impact factor: 5.075

Review 9.  Palliative management of refractory dyspnea in COPD.

Authors:  Hope E Uronis; David C Currow; Amy P Abernethy
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

Review 10.  Hyperinflation and its management in COPD.

Authors:  Luis Puente-Maestu; William W Stringer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.